Tumorigenesis in PDAC is driven by signature gene mutation of KRAS in 90% of cases, with frequent inactivation of tumor suppressor genes such as TP53, SMAD4, and CDKN2A and with complex interactions with the tumor microenvironment [6]. This evidence concerns the gene CDKN2A and neoplasm.